Last reviewed · How we verify

Oxycodone and acetaminophen — Competitive Intelligence Brief

Oxycodone and acetaminophen (Oxycodone and acetaminophen) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Opioid analgesic combination. Area: Pain Management.

marketed Opioid analgesic combination Mu opioid receptor (oxycodone); cyclooxygenase enzymes (acetaminophen) Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

Oxycodone and acetaminophen (Oxycodone and acetaminophen) — University of Puerto Rico. Oxycodone binds to opioid receptors to reduce pain perception, while acetaminophen inhibits prostaglandin synthesis to provide additional analgesic and antipyretic effects.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Oxycodone and acetaminophen TARGET Oxycodone and acetaminophen University of Puerto Rico marketed Opioid analgesic combination Mu opioid receptor (oxycodone); cyclooxygenase enzymes (acetaminophen)
BENZHYDROCODONE BENZHYDROCODONE marketed Opioid analgesic combination; full mu-opioid agonist with non-opioid analgesic Mu-opioid receptors (primary); delta and kappa opioid receptors (secondary); central nervous system pain pathways 2018-01-01
Standard opioid plus methocarbamol Standard opioid plus methocarbamol Prisma Health-Upstate marketed Opioid analgesic combination with skeletal muscle relaxant Mu-opioid receptor (opioid component); central nervous system polysynaptic pathways (methocarbamol component)
Ropivacaine/Fentanyl Ropivacaine/Fentanyl National Institute for Tuberculosis and Lung Diseases, Poland marketed Local anesthetic with opioid analgesic combination Voltage-gated sodium channels (ropivacaine); mu opioid receptor (fentanyl)
dexketoprofen trometamol + tramadol hydrochloride dexketoprofen trometamol + tramadol hydrochloride Kavaklıdere Umut Hospital marketed NSAID + opioid analgesic combination COX-1/COX-2 (dexketoprofen); mu-opioid receptor, norepinephrine transporter, serotonin transporter (tramadol)
Oxycontin/acetominophen Oxycontin/acetominophen University of Rochester marketed Opioid analgesic combination Mu opioid receptor (oxycodone); COX inhibitor (acetaminophen)
Acetaminophen-Hydrocodone Acetaminophen-Hydrocodone Le Bonheur Children's Hospital marketed Opioid analgesic combination Mu opioid receptor (hydrocodone component); prostaglandin synthesis inhibition (acetaminophen component)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Opioid analgesic combination class)

  1. VA Office of Research and Development · 3 drugs in this class
  2. Rothman Institute Orthopaedics · 2 drugs in this class
  3. Labopharm Inc. · 2 drugs in this class
  4. University of Rochester · 2 drugs in this class
  5. Montefiore Medical Center · 2 drugs in this class
  6. Maastricht University Medical Center · 2 drugs in this class
  7. Henry Ford Health System · 1 drug in this class
  8. Daewon Pharmaceutical Co., Ltd. · 1 drug in this class
  9. Albert Einstein College of Medicine · 1 drug in this class
  10. Johnson & Johnson Taiwan Ltd · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Oxycodone and acetaminophen — Competitive Intelligence Brief. https://druglandscape.com/ci/oxycodone-and-acetaminophen. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: